We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Hutchmed (China) Limited (HCM) ORD USD0.10

Sell:229.00p Buy:231.00p 0 Change: 1.00p (0.42%)
FTSE AIM 100:0.17%
Market closed |  Prices as at close on 20 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:229.00p
Buy:231.00p
Change: 1.00p (0.42%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 20 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:229.00p
Buy:231.00p
Change: 1.00p (0.42%)
Market closed |  Prices as at close on 20 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.

Contact details

Address:
48Th Floor, Cheung Kong Center
2 Queen's Road Central


Hong Kong
Telephone:
+852 (0212) 81188
Website:
https://www.hutch-med.com/

Important dates

Future events
There are no future events available.
Past events
Interim results 31 July 2024 31/07/24
AGM 10 May 2024 10/05/24
Annual report 08 April 2024 08/04/24
Final results 01 February 2024 01/02/24

General stock information

EPIC:
HCM
ISIN:
KYG4672N1198
Market cap:
£2.03 billion
Shares in issue:
854.68 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
FTSE AIM 100,FTSE AIM All Share

Key personnel

  • Chi Keung To
    Executive Chairman of the Board
  • Weiguo Su
    Chief Executive Officer, Chief Scientific Officer, Executive Director
  • Chig Fung Cheng
    Chief Financial Officer, Executive Director
  • Karen Atkin
    Chief Operating Officer, Executive Vice President
  • Ming Shi
    Executive Vice President and Head of Research and Development and Chief Medical
  • Zhenping Wu
    Executive Vice President - Pharmaceutical Sciences and Manufacturing
  • Kin Hung Lee
    Senior Vice President - Corporate Finance and Development
  • Hong Chen
    Senior Vice President and Chief Commercial Officer, China
  • Qingmei Wang
    Senior Vice President - Business Development and Strategic Alliances
  • Charles Nixon
    Group General Counsel

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.